Jump to content

Evenamide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 17:59, 19 October 2020 (→‎top: Task 17: replace to-be-deprecated: |name-list-format= (1× replaced; usage: 1 of 1);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Evenamide
Clinical data
Other namesNW-3509; NW-3509A
ATC code
  • None
Identifiers
  • 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H26N2O2
Molar mass278.396 g·mol−1
3D model (JSmol)
  • CCCCOC1=CC=CC(=C1)CCNCC(=O)N(C)C
  • InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
  • Key:GRHBODILPPXVKN-UHFFFAOYSA-N

Evenamide (INNTooltip International Nonproprietary Name) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[5]

See also

References

  1. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
  2. ^ Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
  3. ^ a b Gupta SP (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
  4. ^ Zuliani V, Amori L, Rivara M (2011). "Advances in Design and Development of Sodium Channel Blockers". Ion Channels and Their Inhibitors. pp. 79–115. doi:10.1007/978-3-642-19922-6_4. ISBN 978-3-642-19921-9.
  5. ^ "Newron raised new funds to continue the development of Neurological therapies". Labiotech. 5 February 2015. Archived from the original on 4 March 2016.

External links